[{"ID":"23483_33-2022_NCT03230396","TOPIC_YEAR":2022,"RESPONSE":"The patient is a 20-year-old man, which meets the inclusion criterion of being aged 18-60 years old.\n\nThe patient has no pre-existing oral diseases, including cancer, periodontitis, or mucositis, which meets the exclusion criterion.\n\nThe patient does not have any chewing or swallowing disorders, which meets the exclusion criterion.\n\nThe patient is not pregnant, lactating, or planning to become pregnant during the study, which meets the exclusion criterion.\n\nThe patient does not have any known clotting disorders, which meets the exclusion criterion.\n\nThe patient is willing to follow the investigator instructions and requirements of the protocol, which meets the inclusion criterion.\n\nThe patient is proficient with the English language (both written and verbal), which meets the inclusion criterion.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9628673241},{"ID":"35341_75-2021_NCT00465790","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease.\n\nYes, the patient meets the inclusion criteria for the clinical trial, which requires a diagnosis of Parkinson's disease.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9078532344},{"ID":"6778_15-2021_NCT01986686","TOPIC_YEAR":2021,"RESPONSE":"The patient is an 70-year-old woman with a history of CAD and recently noted abdominal mass who presents with fevers\/rigors and bandemia.\n\nThe patient does not meet the exclusion criteria for the clinical trial, as she does not have prior episode of diverticulitis, right-sided diverticulitis, failure of recovery from first episode, or comorbidities prohibiting surgery.\n\nHowever, the patient does meet the inclusion criteria for the clinical trial, as she has a history of resolved first episode of diverticulitis with abscess (Hinchey class II) who were successfully treated by the standard protocol, and the diagnosis was confirmed by colonoscopy.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9399264152},{"ID":"30943_65-2021_NCT04305639","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 25-year-old man with type 1 diabetes and cardiomyopathy. The clinical trial is for the reliability and validity of the Turkish version of the Dyspnea-ALS-Scale (DALS-15) for patients with Amyotrophic Lateral Sclerosis (ALS). The patient does not have ALS, so they are not eligible for the clinical trial.\n\nTherefore, the patient is \"excluded\" from the clinical trial.","PROBA":0.9295262663},{"ID":"30870_65-2021_NCT03605979","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 25-year-old man with type 1 diabetes.\n\nYes, the patient meets the inclusion criterion of being >18 years old.\n\nThe patient has been treated with insulin pump for more than three months.\n\nYes, the patient has been treated with insulin pump for more than three months.\n\nThe patient has had hypoglycemia unawareness with a hypoglycemia perception threshold below 60 mg\/dL and\/or had at least one severe hypoglycemia event in the previous year.\n\nNo, the patient does not meet this criterion. The patient does not have hypoglycemia unawareness and has not had a severe hypoglycemia event in the previous year.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9545367469},{"ID":"14057_30-2021_NCT01941784","TOPIC_YEAR":2021,"RESPONSE":"The patient does not have breast cancer, so they do not meet the inclusion criteria for the clinical trial.\n\nTherefore, the patient is \"excluded\" from the clinical trial.","PROBA":0.8376261401},{"ID":"33687_71-2021_NCT02518685","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 34-year-old woman who is obese (BMI 41.5) and has a history of obesity for at least 2 years, with a history of failure of medically or commercially supervised weight loss programs. She also has obesity-related comorbidities such as sleep apnea, PCO, and dissatisfaction with her body shape.\n\nBased on the inclusion criteria, the patient is eligible for the clinical trial.\n\nThe patient meets the age requirement (22-60 years old) and the BMI requirement (30.0-40.0 kg\/m2, inclusive). She also has obesity-related comorbidities, which are listed as requirements for eligibility. Additionally, she has a history of failure of medically or commercially supervised weight loss programs, which is also listed as a requirement.\n\nHowever, the patient does not meet the exclusion criteria, such as pregnancy or nursing, hormonal or genetic cause for obesity, prior history of any GI surgery or endoscopic intervention, chronic use of medications likely to contribute to weight gain or prevent weight loss, gastric or duodenal ulcers, positive for H. pylori, history of severe dyspepsia, GI tract motility disorders, history of inflammatory disease of GI tract, coeliac disease, pancreatitis, portal hypertension, cirrhosis, and\/or varices, diabetes treated with insulin, HbA1c >7.5%, uncontrolled thyroid and adrenal gland disease or uncontrolled hypertension, history of certain cardiac events, localized or systemic infection, anemia, history of asthma likely to require systemic steroid therapy, autoimmune connective tissue disorders or immunocompromised, history of malignancy except non-melanoma skin cancer, continuous use of ulcerogenic medication, on anticoagulation or antiplatelet therapy, use of weight-loss medication, in other weight-loss program, unable to take proton pump inhibitor, abnormal laboratory values or EKG, inability to walk at least 0.8 kilometers per day, planned surgical procedure that can impact the conduct of the study, known allergy to any component materials in the TPSS, smoker or user of nicotine product, substance abuse, severe, uncontrolled psychiatric illness, recent inpatient psychiatric treatment, moderate depression, bulimia nervosa or binge eating disorder, participation in another clinical study, employee or family member of Sponsor or study staff.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9706373255},{"ID":"35806_75-2021_NCT04651140","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 55-year-old man with Parkinson's disease.\n\nYes, the patient meets the inclusion criteria of the clinical trial, which requires participants to be diagnosed with primary Parkinson's disease and be between 55 and 65 years old.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9062450316},{"ID":"35568_75-2021_NCT02703844","TOPIC_YEAR":2021,"RESPONSE":"The patient has been diagnosed with Parkinson's disease, which is an inclusion criterion for the clinical trial.\n\nThe patient does not have a premorbid psychiatric history, which is an exclusion criterion for the clinical trial.\n\nThe patient does not have previous exposure to neurostimulation, which is an exclusion criterion for the clinical trial.\n\nThe patient does not have inner ear pathology, which is an exclusion criterion for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9521792007},{"ID":"16878_36-2021_NCT00269048","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman who is not pregnant and does not have any history of cardiovascular disease. She is overweight and has sleep apnea, PCO, and dissatisfaction with her body shape. She does not have any of the exclusion criteria listed for the clinical trial.\n\nTherefore, based on the information provided, the patient would be eligible for the clinical trial.","PROBA":0.8873255562},{"ID":"5454_12-2021_NCT03433274","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have symptomatic, moderate-to-severe or severe mitral regurgitation?\nYes, the patient has severe mitral regurgitation.\n\n#2: Is the patient's NYHA Functional Classification \u2265 II?\nYes, the patient's NYHA Functional Classification is II.\n\n#3: Has the patient been adequately treated per applicable standards?\nYes, the patient has been adequately treated per applicable standards.\n\n#4: Does the patient have any planned surgical\/interventional procedures within 60 days prior to or following subject randomization?\nNo, the patient does not have any planned surgical\/interventional procedures within 60 days prior to or following subject randomization.\n\n#5: Does the patient have any non-cardiac comorbidities that are likely to result in a life expectancy of less than 12 months?\nNo, the patient does not have any non-cardiac comorbidities that are likely to result in a life expectancy of less than 12 months.\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9622617659},{"ID":"14277_30-2021_NCT04518475","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 33-year-old woman with Hashimoto's thyroiditis, which is an autoimmune disease that affects the thyroid gland. The clinical trial is for the management of primary immune thrombocytopenia (ITP) in adults.\n\nITP is a rare autoimmune disorder that affects the platelets, and the clinical trial is specifically for patients who have not responded to or have relapsed after previous treatment of ITP. Hashimoto's thyroiditis is a different autoimmune disease that affects the thyroid gland, and it is not related to ITP.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9201476198},{"ID":"5418_12-2021_NCT02879825","TOPIC_YEAR":2021,"RESPONSE":"The patient has Marfan's syndrome and known severe mitral valve prolapse with regurgitation.\n\nYes, the patient has a diagnosis of mitral valve prolapse, which meets the inclusion criterion.\n\nThe patient also has severe regurgitation, which is not an exclusion criterion.\n\nThe patient is above 18 years old, which meets the inclusion criterion.\n\nThe patient does not have any contraindications to MRI or exercise ECG, which meets the inclusion criterion.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9208928974},{"ID":"14072_30-2021_NCT02112643","TOPIC_YEAR":2021,"RESPONSE":"#1: Is the patient at least 18 years old?\nYes, the patient is 33 years old, which is greater than 18 years old.\n\n#2: Is the patient able to provide informed consent?\nYes, the patient is able to provide informed consent.\n\n#3: Does the patient have mild thyroid eye disease requiring no past treatment other than ophthalmic drops or ointment?\nNo, the patient does not have mild thyroid eye disease. The patient has Hashimoto's thyroiditis, which is a different condition.\n\n#4: Is the patient euthyroid?\nNo, the patient is not euthyroid. The patient has low free T4 and high TSH levels, which indicates hypothyroidism.\n\n#5: Has the patient been treated with radioiodine therapy?\nNo, the patient has not been treated with radioiodine therapy.\n\n#6: Has the patient been treated with any selenium supplementation?\nNo, the patient has not been treated with any selenium supplementation.\n\nBased on the criteria, the patient is not eligible for the clinical trial.","PROBA":0.9415049743},{"ID":"17194_36-2021_NCT02784977","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have sleep apnea?\nNo, the patient does not have sleep apnea.\n\n#2: Is the patient undergoing sleep study for suspicion of obstructive sleep apnea?\nNo, the patient is not undergoing sleep study for suspicion of obstructive sleep apnea.\n\n#3: Does the patient have any of the exclusion criteria?\nNo, the patient does not have any of the exclusion criteria.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9248413461},{"ID":"30789_65-2021_NCT02657213","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have type 1 diabetes?\nYes, the patient has type 1 diabetes.\n\n#2: Does the patient have at least 2 episodes of severe hypoglycemia within 12 months before the study enrollment?\nNo, the patient does not have at least 2 episodes of severe hypoglycemia within 12 months before the study enrollment.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9402912534},{"ID":"33975_71-2021_NCT04841057","TOPIC_YEAR":2021,"RESPONSE":"#1: Age greater than 18\nEligible\n\n#2: Body mass index of 40-60 kg\/m2\nEligible\n\n#3: Meet insurance criteria\nEligible\n\n#4: Planned laparoscopic Roux-en-Y gastric bypass\nEligible\n\n#5: Willingness to have blood collected before and after surgical procedure at defined points and collect and mail stool sample before operation and at defined post-operative time points\nEligible\n\nBased on the criteria, the patient is eligible for the clinical trial.","PROBA":0.9480189976},{"ID":"30795_65-2021_NCT02719509","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 25-year-old man with a chief complaint of shortness of breath and fatigue during activities, which matches the inclusion criteria of the clinical trial.\n\nThe patient is also diagnosed with cardiomyopathy, which is a heart condition that can cause shortness of breath and fatigue. This further supports the patient's eligibility for the clinical trial.\n\nTherefore, based on the information provided, the patient is eligible for the clinical trial.","PROBA":0.923488014},{"ID":"17346_36-2021_NCT04083768","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman who is not pregnant. Therefore, she does not meet the inclusion criteria of being pregnant at term via elective cesarean section.\n\nThe patient's BMI is 41.54, which is above the maximum limit of 35 kg\/m2 specified in the inclusion criteria. Therefore, she does not meet the inclusion criteria.\n\nThe patient does not have any of the exclusion criteria, such as transverse lie, fetal macrosomia, uterine abnormalities, polyhydramnios, oligohydramnios, intrauterine growth restriction, gestational or nongestational hypertension, diabetes, eclampsia, hypertensive disorder, or any condition associated with autonomic neuropathy.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9433428791},{"ID":"27514_40-2022_NCT00510042","TOPIC_YEAR":2022,"RESPONSE":"The patient has prolonged oral bleeding after a tooth extraction, which suggests that she may have a bleeding disorder.\n\nThe patient's mother and grandmother also had excessive bleeding during menstrual periods, which suggests that there may be a familial component to the patient's bleeding disorder.\n\nThe patient's laboratory findings show a normal platelet count and an abnormal ristocetin cofactor assay, as well as CB <= 0.30 IU\/mL and FVIII:C <= 0.40 IU\/mL. These findings are consistent with a diagnosis of von Willebrand disease.\n\nBased on the patient's symptoms and laboratory findings, she meets the inclusion criteria for the clinical trial. Therefore, the patient is eligible for the clinical trial.","PROBA":0.9354884761},{"ID":"30754_65-2021_NCT02402803","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 25-year-old man with type 1 diabetes and cardiomyopathy.\n\nThe clinical trial is for patients initiated on statin therapy in the clinical setting.\n\nThe patient is not currently taking statins, so they do not meet the inclusion criteria.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9252206239},{"ID":"6745_15-2021_NCT01713452","TOPIC_YEAR":2021,"RESPONSE":"The patient has a history of diverticulitis, which is an indication for initial ostomy formation. Therefore, the patient meets the inclusion criteria.\n\nHowever, the patient's stoma site is not left open to heal by secondary intention due to gross contamination, and the stoma site is not re-used (i.e., the same stoma site used for the formation of a new ostomy). Therefore, the patient does not meet any of the exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9425676656},{"ID":"17329_36-2021_NCT03860233","TOPIC_YEAR":2021,"RESPONSE":"The patient is a woman who is 32 years old and has obesity, which is an inclusion criterion for the clinical trial.\n\nHowever, the patient does not have obstructive sleep apnea (OSA), which is a requirement for participation in the clinical trial.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial and therefore would not be eligible to participate.","PROBA":0.9015959082},{"ID":"16938_36-2021_NCT00653393","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old obese woman.\n\nINCLUSION CRITERIA:\n\n* Is the individual healthy, nonsmoking, normal adult man or woman who volunteers to participate?\n* Is s\/he at least 18 years of age?\n* Is his\/her BMI between 19 and 30, exclusive?\n\nThe patient meets the first two criteria but not the third criterion. Her BMI is 41.54, which is above 30 and exclusive of the range. Therefore, the patient is not eligible for the clinical trial.","PROBA":0.9175112944},{"ID":"33785_71-2021_NCT03231423","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 34-year-old obese woman, which meets the inclusion criteria of being a morbidly obese patient.\n\nThe patient is considering a laparoscopic gastric bypass surgery, which is the intervention being studied in the clinical trial.\n\nThe patient does not have any of the exclusion criteria, such as being under 18 years of age, having cirrhosis, or having previously undergone obesity surgery (revision surgery).\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9372478478},{"ID":"28067_40-2022_NCT04467736","TOPIC_YEAR":2022,"RESPONSE":"The patient is a 23-year-old female who has prolonged oral bleeding after a tooth extraction.\n\nYes, the patient meets the inclusion criteria of being at least 18 years old and having a need for ARP after tooth extraction with >50% buccal bone still present.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9375819931},{"ID":"6824_15-2021_NCT02347618","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 70-year-old woman with a history of CAD and recently noted abdominal mass who presents with fevers\/rigors and bandemia.\n\nYes, the patient meets the inclusion criteria for the clinical trial:\n\n1. Patient with pathologically proven diagnosis of adenocarcinoma of the head of the pancreas\n\nThe patient has a pathologically proven diagnosis of pancreatic adenocarcinoma.\n\n2. CT w\/ contrast using the pancreas protocol or MRI of the abdomen with contrast within 6 weeks prior to registration\n\nThe patient underwent a CT abdomen without contrast, which is not within the specified time frame. However, the patient did undergo an EUS with biopsy, which provides a more recent and accurate diagnosis.\n\n3. CT chest or PET\/CT within 6 weeks prior to registration\n\nThe patient did not undergo a CT chest or PET\/CT within the specified time frame.\n\n4. Clinically determined to be resectable based on NCCN Criteria\n\nThe patient is clinically determined to be resectable based on NCCN Criteria.\n\n5. No radiographic evidence of superior mesenteric vein or portal vein distortion\n\nThe patient does not have radiographic evidence of superior mesenteric vein or portal vein distortion.\n\n6. No evidence of distant metastasis\n\nThe patient does not have evidence of distant metastasis.\n\n7. Clear fat planes around the celiac axis, hepatic artery, and superior mesenteric artery\n\nThe patient has clear fat planes around the celiac axis, hepatic artery, and superior mesenteric artery.\n\n8. No enlarged lymph nodes per CT criteria or PET avid lymph nodes\n\nThe patient does not have enlarged lymph nodes per CT criteria or PET avid lymph nodes.\n\n9. No lymphadenopathy outside the surgical field (i.e. celiac or para-aortic adenopathy)\n\nThe patient does not have lymphadenopathy outside the surgical field.\n\n10. Adequate cardiopulmonary reserves to tolerate surgery\n\nThe patient has adequate cardiopulmonary reserves to tolerate surgery.\n\n11. Karnofsky performance status > 70\n\nThe patient has a Karnofsky performance status > 70.\n\n12. Age >18\n\nThe patient is over the age of 18.\n\n13. Adequate bone marrow function defined as follows:\n\nThe patient has adequate bone marrow function.\n\n14. Absolute neutrophil count (ANC) > 1800 cells\/mm3\n\nThe patient has an absolute neutrophil count (ANC) > 1800 cells\/mm3.\n\n15. Platelets \u2265 100,000 cells\/mm3\n\nThe patient has platelets \u2265 100,000 cells\/mm3.\n\n16. Hemoglobin > 8.0 g\/dl (Note: The use of transfusion or other intervention to achieve Hgb > 8 g\/dl is acceptable.)\n\nThe patient has hemoglobin > 8.0 g\/dl.\n\n17. Pregnancy test must be negative for women of childbearing potential within 7 days prior to study entry\n\nThe patient is not pregnant.\n\n18. Patient must sign study specific informed consent prior to study entry\n\nThe patient has signed the study specific informed consent prior to study entry.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9778171139},{"ID":"7065_15-2021_NCT04500405","TOPIC_YEAR":2021,"RESPONSE":"The patient is not eligible for the clinical trial because the trial is only for patients who visited the Emergency Department during March, 2012 and September, 2018, and the patient did not visit the ED during those months. The patient was admitted to the hospital with a diagnosis of pancreatic adenocarcinoma, not diverticulitis.","PROBA":0.8831240156},{"ID":"35720_75-2021_NCT03956979","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 55-year-old man with Parkinson's disease.\n\nYes, the patient meets the inclusion criterion of being between 18 and 80 years of age.\n\nYes, the patient has been diagnosed with idiopathic Parkinson's disease that requires treatment with levodopa, and has experienced dyskinesia over a period of at least 3 months prior to Screening Visit.\n\nYes, the patient has stable peak-effect dyskinesia and has more than one hour of \"ON\" time with troublesome dyskinesia during daily waking hours on a 24-hour PD subject diary.\n\nYes, the patient is on a stable levodopa dosing regimen requiring at least 3 dose administrations but no more than 6 dose administrations per day.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.952736205},{"ID":"24994_53-2021_NCT00724659","TOPIC_YEAR":2021,"RESPONSE":"$}}%>\n\nNo, the patient is not eligible for the clinical trial. The patient does not meet the inclusion criteria of having a clinically ordered arthrogram. Additionally, the patient is not pregnant and is over the age of 18, so they do not meet any of the exclusion criteria. Therefore, the patient is not eligible for the clinical trial.","PROBA":0.9170357342},{"ID":"33644_71-2021_NCT02153021","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 34-year-old woman with a BMI of 41.5, which meets the inclusion criterion of BMI \u2265 30.\n\nThe patient does not use contraceptive use, cortisone, anti-epileptic drugs, or have a history of kidney and heart disease, alcohol abuse, smoking, or use of supplemental vitamins, which meets the exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9467372388},{"ID":"14003_30-2021_NCT01240499","TOPIC_YEAR":2021,"RESPONSE":"The patient is a premenopausal woman (check).\nShe is overweight (check).\nShe has been unsuccessful in previous weight loss attempts (check).\nShe is currently not dieting to lose weight (check).\nShe is not taking oral contraceptives or postmenopausal status (check).\nShe is not pregnant or lactating (check).\nShe does not have any metabolic or important psychological disorders (check).\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9298138991},{"ID":"16957_36-2021_NCT00842777","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman, which is outside of the age range of 7-12 years. Therefore, the patient is not eligible for the clinical trial.","PROBA":0.8729238505},{"ID":"27962_40-2022_NCT03732872","TOPIC_YEAR":2022,"RESPONSE":"The patient does not have a history of arecanut chewing habit, so they do not meet the first inclusion criterion.\n\nThe patient does not have clinical symptoms of OSMF, so they do not meet the second inclusion criterion.\n\nThe patient is not a healthy human volunteer, so they do not meet the third inclusion criterion.\n\nThe patient has a history of prolonged oral bleeding after tooth extraction, which suggests they may have a bleeding disorder, so they meet the exclusion criterion.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9370059278},{"ID":"5404_12-2021_NCT02734160","TOPIC_YEAR":2021,"RESPONSE":"The patient has Marfan syndrome and known severe mitral valve prolapse with regurgitation, which is an exclusion criterion for the clinical trial. Therefore, the patient is not eligible for the clinical trial.","PROBA":0.9073253793},{"ID":"17056_36-2021_NCT01675713","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old obese woman.\n\nYes, the patient meets the inclusion criteria of being morbidly obese.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.8792452932},{"ID":"17003_36-2021_NCT01207609","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman, which meets the age inclusion criterion of 18-60 years.\n\nThe patient's BMI is 41.54, which is well above the upper limit of the inclusion criterion of BMI 35-39.9 kg\/m2. Therefore, the patient meets the BMI inclusion criterion.\n\nThe patient has one or more severe co-morbid conditions, specifically sleep apnea, PCO, and dissatisfaction with her body shape, which meets the inclusion criterion.\n\nThe patient has a history of obesity for at least 5 years, which meets the inclusion criterion.\n\nThe patient has a history of at least 6 months of documented failures with traditional non-surgical weight loss methods, which meets the inclusion criterion.\n\nThe patient is willing to comply with dietary restrictions required by the protocol and willing to follow protocol requirements, which meets the inclusion criterion.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9494174608},{"ID":"17413_36-2021_NCT04575194","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman with a BMI of 41.54, which meets the inclusion criteria of BMI \u2265 30 kg\/m2.\n\nThe patient does not have any clinical contraindications for the administration of liraglutide or bupropion\/naltrexone, as she does not have any of the exclusion criteria listed (e.g. bariatric surgery, diabetes type 2, active malignancy, medication that affects weight).\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9256612577},{"ID":"30413_65-2021_NCT00200993","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 25-year-old man with type 1 diabetes, which is an exclusion criterion for the clinical trial. Therefore, the patient is not eligible for the clinical trial.","PROBA":0.9204663412},{"ID":"11421_17-2022_NCT00458575","TOPIC_YEAR":2022,"RESPONSE":"The patient is a 67-year-old man with slowly worsening vision in both eyes, which suggests that he may have retinitis pigmentosa, a disease that leads to loss of vision and blindness. This meets the inclusion criterion of having a confirmed diagnosis of retinitis pigmentosa.\n\nHowever, the patient does not meet the exclusion criterion of having other significant ophthalmologic diseases or any other ophthalmologic condition that interferes with ophthalmologic examination.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9344837592},{"ID":"27968_40-2022_NCT03774888","TOPIC_YEAR":2022,"RESPONSE":"The patient is a 23-year-old female who has prolonged oral bleeding after a tooth extraction.\n\nNo, the patient is not eligible for the clinical trial. The clinical trial is for patients who need implants to replace missing teeth and have insufficient alveolar ridge width. The patient does not meet these criteria as she is experiencing prolonged oral bleeding after a tooth extraction, but does not need implants.","PROBA":0.9250625602},{"ID":"33879_71-2021_NCT04023864","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 34-year-old woman who is overweight (BMI 41.5) and has a history of unsuccessful attempts to lose weight using antiobesity agents and appetite suppressants. She is considering a laparoscopic gastric bypass.\n\nINCLUSION CRITERIA:\n\n* Males and females aged between 19 and 65 years at the screening\n* Participants who were BMI 25~29.9 kg\/m^2\n\nThe patient does not meet the BMI criterion (BMI 41.5) and is therefore not eligible for the clinical trial.\n\nEXCLUSION CRITERIA:\n\n* Participants who decrease 10% more of weight within 3 months period to the screening examination\n* Participants taking for products affecting body weight within 4 weeks before the screening examination\n\nThe patient is not excluded based on these criteria.\n\nThe patient is not eligible for the clinical trial.","PROBA":0.9428163192},{"ID":"35325_75-2021_NCT00296959","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Does the patient have levodopa-induced dyskinesia?\nNo, the patient does not have levodopa-induced dyskinesia.\n\n#3: Is the patient's Hoehn-Yahr stage 5 or higher when \"off\"?\nNo, the patient's Hoehn-Yahr stage is 1.\n\n#4: Does the patient have any of the exclusion criteria?\nNo, the patient does not have any of the exclusion criteria.\n\nTherefore, the patient is not eligible for the clinical trial.","PROBA":0.9297241641},{"ID":"17453_36-2021_NCT04861701","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman, which meets the age inclusion criterion of 20-65 years old.\n\nThe patient does not mention hot flashes in her note, so she does not meet the inclusion criterion of experiencing hot flashes.\n\nThe patient does not have any medical conditions that would limit her ability to participate in exercise, so she does not meet the exclusion criterion of having a medical condition that could affect hot flashes.\n\nThe patient does not mention taking any hormone therapy, psychotropic medications, or sleeping pills for the past 6 months, so she meets the exclusion criterion of not having current therapies that could affect hot flashes.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nC: Not eligible","PROBA":0.9251455986},{"ID":"17018_36-2021_NCT01321034","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman, which meets the age inclusion criterion of >18 and <80 years.\n\nHer LDL cholesterol level is 180 mg\/dL, which is above the inclusion criterion of 70-190 mg\/dL.\n\nHer triglycerides level is 150 mg\/dL, which is within the inclusion criterion of <500 mg\/dL.\n\nShe has at least 2 Lp(a) determinations previous to the beginning of the study without differences >20% or > 20 mg\/dL, which meets the inclusion criterion.\n\nShe has no lipid lowering therapy or on stable doses in the last 3 months, which meets the exclusion criterion.\n\nShe does not have any of the exclusion criteria, such as liver disease or liver enzymes >2 times higher than reference values, active peptic ulcer, clinical gout in the last year, uncontrolled diabetes (HbA1c >8%), or enrolment in other drug clinical trial in the previous 3 months.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9601869921},{"ID":"6663_15-2021_NCT01015820","TOPIC_YEAR":2021,"RESPONSE":"The patient is 70 years old, which meets the inclusion criterion of age 18 years or older.\n\nThe patient has a history of coronary artery disease, mitral valve prolapse, atrial fibrillation, hyperlipemia, hypertension, chronic kidney disease, and hypothyroidism, but these conditions are not exclusion criteria.\n\nThe patient has a history of pancreatic adenocarcinoma, which meets the inclusion criterion of known adenocarcinoma of the pancreas.\n\nThe patient has undergone EUS with biopsy, which is consistent with the inclusion criterion of patients with known malignant lesion in the pancreas or duodenum.\n\nThe patient does not have any of the exclusion criteria, such as unable to obtain biopsy specimen, presence of malignant lesion other than pancreas adenocarcinoma, known familial disorder with high risk of pancreas cancer development, significant family history of pancreatic cancer, presence of premalignant lesions, or active visible inflammation\/ulcer in the stomach or duodenum.\n\nTherefore, the patient is eligible for the clinical trial.","PROBA":0.9487400873},{"ID":"14112_30-2021_NCT02633475","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 33-year-old woman with Hashimoto's thyroiditis, which is an autoimmune disorder.\n\nThe clinical trial is for the correlation between the interleukin-10 (IL-10)-1082A\/G polymorphism and idiopathic recurrent miscarriage (IRM) of Chinese Han.\n\nThe patient does not have a history of recurrent miscarriage, and she does not meet any of the exclusion criteria for the clinical trial.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nC: Irrelevant","PROBA":0.9313737085},{"ID":"27930_40-2022_NCT03521583","TOPIC_YEAR":2022,"RESPONSE":"The patient has prolonged oral bleeding after a tooth extraction, which suggests that she may have a bleeding disorder.\n\nThe patient's laboratory findings show that her VWF:Ag and VWF:RCo levels are normal, but her VWF:CB and FVIII:C levels are below the inclusion criteria of 0.30 IU\/mL and 0.40 IU\/mL, respectively.\n\nTherefore, the patient meets the inclusion criteria for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9249959647},{"ID":"6859_15-2021_NCT02703545","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 70-year-old woman with a history of CAD and recent abdominal mass, who was diagnosed with pancreatic adenocarcinoma.\n\nYes, the patient is eligible for the clinical trial. The patient meets the inclusion criteria of having an elevated risk of pancreas cancer and being diagnosed with pancreatic adenocarcinoma.","PROBA":0.9076190261},{"ID":"17361_36-2021_NCT04150445","TOPIC_YEAR":2021,"RESPONSE":"The patient is a 32-year-old woman who is overweight (BMI 41.54) and has several comorbidities, including hypertension, prediabetes, and hyperlipidemia. These conditions meet the inclusion criteria for the clinical trial.\n\nHowever, the patient has a history of previous weight loss treatment within the last 6 months, which is an exclusion criterion for the trial. Therefore, the patient would be excluded from the clinical trial.\n\nSo, the patient is \"excluded\" from the clinical trial.","PROBA":0.8974067028}]
